YIH
PRME icon

Y-Intercept (HK)’s Prime Medicine PRME Stock Holding History

Y-Intercept (HK)’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,193
Closed -$90.3K – 1682
2023
Q4 		$90.3K Buy
+10,193
New +$78.5K 0.01% 1104

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Y-Intercept (HK)'s PRME Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Prime Medicine (PRME) in Q1 2024, closing a stake of 10,193 shares — an estimated $90.3K sold.

Y-Intercept (HK) first reported a position in PRME in Q4 2023 and held it in 1 quarter. The position peaked at $90.3K in Q4 2023. 115 funds tracked by Wall St. Rank hold PRME as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Prime Medicine position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 10,193 Prime Medicine shares in Q1 2024, an estimated $90.3K.
  • Y-Intercept (HK) first reported a position in Prime Medicine in Q4 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Prime Medicine position peaked at $90.3K in Q4 2023.
  • 115 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.